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Abstract: The synthesis and cytotoxic activity of a series of twenty six aroyl and 
heteroaroyl selenylacetic acid derivatives of general formula Ar-CO-Se-CH2-COOH or 
Heterar-CO-Se-CH2-COOH are reported. The synthesis was carried out by reaction of acyl 
chlorides with sodium hydrogen selenide, prepared in situ, and this led to the formation of 
sodium aroylselenides that subsequently reacted with α-bromoacetic acid to produce the 
corresponding selenylacetic acid derivatives. All of the compounds were tested against a 
prostate cancer cell line (PC-3) and some of the more active compounds were assessed 
against a panel of four human cancer cell lines (CCRF-CEM, HTB-54, HT-29, MCF-7) 
and one mammary gland-derived non-malignant cell line (184B5). Some of the compounds 
exhibited remarkable cytotoxic and antiproliferative activities against MCF-7 and PC-3 
that were higher than those of the reference compounds doxorubicin and etoposide, 
respectively. For example, in MCF-7 when Ar = phenyl, 3,5-dimethoxyphenyl or benzyl 
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the TGI values were 3.69, 4.18 and 6.19 μM. On the other hand, in PC-3 these compounds 
showed values of 6.8, 4.0 and 2.9 μM. Furthermore, benzoylselenylacetic acid did not 
provoke apoptosis nor did it perturb the cell cycle in MCF-7. 
Keywords: selenylacetic acid; cytotoxicity; apoptosis 
 
Introduction 
Cancer is currently one of the leading causes of death worldwide and could become the most 
common cause in the future [1]. Our understanding of the biology of cancer has undoubtedly improved 
in the last decade. One characteristic of cancer cells is their highly proliferative nature. Consequently, 
inhibition of proliferative pathways is considered an effective strategy to fight cancer and a great deal 
of attention has recently been paid to the discovery and development of new, more selective anticancer 
agents. The results of numerous studies indicate that selenium is an essential trace element [2,3] with 
structural and enzymatic roles for viral suppression and against AIDS. This element is also implicated 
in delaying the aging process. Selenium deficiency has been linked to a number of disorders such as 
heart disease, diabetes and cancer. Selenium compounds have attracted renewed interest as 
chemopreventive agents for human cancer on the basis of the pioneering intervention study carried out 
by Clark and Combs [4]. Later epidemiological and clinical intervention studies support the protective 
role of selenium against the development of prostate cancer [5-7]. More recently, mounting evidence 
indicates that Se compounds inhibit neoplasm of lung, colon, mammary gland, sarcoma and 
glioblastoma [8,9]. In addition, selenium supplementation [10-12] could provide significant 
therapeutic potential for patients with gastrointestinal, liver and head and neck cancers.  
Furthermore, literature reports have consistently shown that the dose and chemical forms of 
selenium [13,14] are determinant factors in anticancer activity, with organic Se compounds being 
more bioavailable than the inorganic forms.  
Several chemical forms are under investigation for their potential as candidate drugs and these 
include methylseleno derivatives such as methylselenocysteine [15], p-xylylbis(methylselenide) [16] 
and methylseleninic acid [17], compounds with selenium in the heterocyclic ring as in selenazolidines 
[18], ebselen [19], D-501036 [20], BBSKE [21] or the presence of a selenide function in a symmetrical 
structure such as diphenyl-, dimethyl-, dibenzylselenide [22-24], bis(3-methyl-4-pyridyl)selenide [25] 
and di(3-indolyl)selenide [26]. 
On the other hand, the metabolism of selenium compounds is critical for activity and at least two 
selenium metabolite pools, hydrogen selenide and methylselenol [27,28], that induce distinct types of 
antiangiogenesis, apoptosis, and cell cycle responses, have been implicated as active metabolites for 
the anticancer effects. 
Based on the interesting and widely observed antitumoral activity of selenium compounds and our 
own experience in this field [29,30], we report here the synthesis, biological evaluation and molecular 
modelling study of a group of selenylacetic acid derivatives 1–26, (Figure 1) as potential agents in 
cancer therapy. 
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Figure 1. General formula of compounds. 
 
R: aryl, substituted aryl, arylalkyl, heteroaryl. 
Among the strategies adopted for the design of these structures, particular consideration was given 
to the following approaches: 
(a) The use of the selenide function due to the facile scission of Se from the organic moiety in these 
types of compounds. In addition, this proposed preliminary hypothesis concerning the action 
mechanism of these derivatives, related to the possible scission of Se from the organic moiety, 
allow us to determine the bond order. According to the Molecular Orbital Theory, the bond order 
(b.o.) is equivalent to the number of electrons in the antibonding molecular orbital minus the 
number of electrons in the bonding molecular orbital divided by two. This parameter can be taken 
as a quantitative descriptor for the bond strength and can be related to the aforementioned Se 
scission. 
(b) The appropriate choice of the substituent on the phenyl ring was made according to a synthetic 
accessibility and with the aim of assessing the following aspects: 
(b.1) Influence of the substituents on the Se charge and bond stability, as well as on the acidic 
character of the derivatives, expressed as pKa. 
(b.2) Modulation of the electronic distribution over the aromatic moiety with a variety of electron-
donating and electron-withdrawing substituents, placed at different position with respect to the 
lateral chain. 
(b.3) Molecular volume, conformational behaviour and hydrophobic character (expressed as 
AlogP), considering the presence of the keto moiety, the aromatic/heteroaromatic ring, the 
methylene bridge and the carboxylic moiety as the structural basic pattern. 
Results and Discussion 
Chemistry 
The synthesis of the title compounds 1–26 was carried out as depicted in Scheme 1. In the first step, 
sodium hydrogen selenide was produced by reaction of powdered grey selenium with metallic 
hydrides in an appropriate medium. In the second step, the aroyl or heteroaroyl chloride was reacted 
with sodium hydrogen selenide to produce the intermediate sodium aroyl selenides. The last step 
involved the formation of selenylacetic acids 1–26 by treatment of this intermediate with α-
bromoacetic acid. This synthesis was based on a published procedure with modifications [31] 
following our own protocol. 
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Scheme 1. Synthesis of compounds 1–26. 
 
 
The compounds were obtained in yields from 3 to 78%. The analytical data are shown in Table 1. 
The purity levels of compounds 1–26 were assessed by TLC and elemental analyses and their 
structures were identified from spectroscopic data (IR, 1H NMR). The IR spectra of these compounds 
revealed intense absorption bands in the ranges 1,720–1,700 cm–1 and 1,690–1,665 cm–1, assigned to 
carboxyl and carbonyl groups, respectively. The frequencies of these absorptions varied according to 
the substitution pattern on the arylidene ring. As expected, a decrease in the carbonyl absorption 
frequencies was observed for compounds having electron-donating groups such as methylenedioxy, 
trimethoxy or tert-butyl attached to the benzylidene ring in comparison to electron-withdrawing 
groups (chloro, bromo). 
Biological Evaluation 
Cytotoxic activity in PC-3 
Initially, the new compounds 1–26 were evaluated for their in vitro cytotoxic activity against a 
human prostate cancer cell line (PC-3, ATCC, Manassas, VA, USA) using the MTT assay [32]. We 
selected this cell line because there are numerous clinical trials that show the activity of selenium 
compounds in the reduction of prostate cancer [5,9,15,16]. The results are tabulated as IC50 values. All 
experiments were independently performed at least three times and the values were calculated after 72 
hours exposure (drug concentrations of 2, 5, 7 and 10 μM). The results are shown in Table 2.  
The maximum cytotoxic activity was exhibited by compounds 1, 2, 11, 14 and 21. By comparing 
the activities of compounds with those of methylseleninic acid and etoposide, both effective drugs 
against prostate cancer that have been employed as controls for cytotoxic assays, the results revealed 
that three of the new compounds  −1, 11, 14 − were more active than methylseleninic acid and 
etoposide and that five were better than etoposide. It is noteworthy that the introduction of a new 
methoxy groups in the 4-position in 14 to give 15 results in suppression of the antitumour activity on 
the PC-3 cell line. These findings, along with the observed antitumour activity of compound 14, 
suggest that the activity of the compounds depends on the location of the methoxy substituents on the 
phenyl ring. With the aim of evaluating the preliminary structure-activity relationships to gain an 
understanding of the activity shown by such compounds as antitumorals, we carried out a molecular 
modelling study on the aforementioned derivatives. 
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Table 1. Physical constants for compounds 1–26. 
 
Ref. R Yield (%) 
M. p. 
(ºC) Recryst. Solvent CHN Anal (%) Calcd/Found 
1 phenyl 75 83a Toluene C9H8O3Se C, 44.44/44.47; H, 3.29/3.24; N, 0.00/0.00. 
2 4-cyanophenyl 78 147a Toluene C10H7NO3Se C, 44.77/44.85; H, 2.61/2.67; N, 5.22/4.98. 
3 4-(trifluoromethyl)phenyl 62 108a Toluene C10H7F3O3Se C, 38.58/38.73; H, 2.25/2.15; N, 0.00/0.00. 
4 4-chlorophenyl 19 135-136b,c Toluene C9H7ClO3Se C, 38.95/38.71; H, 2.54/2.43; N, 0.00/0.00. 
5 4-methylphenyl 53 92a Toluene C10H1003Se C, 44.69/44.95; H, 3.89/3.89; N, 0.00/0.00. 
6 4-(tert-butyl)phenyl 19 99-103b,c Chloroform C13H16O3Se C, 52.18/52.04; H, 5.39/5.31; N, 0.00/0.05. 
7 4-methoxyphenyl 16 104-107b Chloroform/Carbon tetrachloride C10H10O4Se C, 43.97/43.49; H, 3.69/3.52; N, 0.00/0.00. 
8 2-chlorophenyl 44 123-125b Carbon tetrachloride C9H7ClO3Se C, 38.95/38.97; H, 2.54/2.52; N, 0.00/0.06. 
9 2-bromophenyl 32 124-128b Carbon tetrachloride C9H7BrO3Se C, 33.57/33.14; H, 2.19/2.02; N, 0.00/0.20. 
10 2-iodophenyl 3 105-108b Carbon tetrachloride C9H7IO3Se C, 29.29/29.14; H, 1.91/1.92; N, 0.00/0.05. 
11 benzyl 48 74a Toluene C9H10O3Se C, 46.69/46.87; H, 3.89/3.89; N, 0.00/0.00. 
12 2-phenylethyl 11 65-69b Hexane C11H12O3S ¼ H2O C, 47.93/48.06; H, 4.57/4.47; N, 0.00/0.18. 
13 3,5-dichlorophenyl 17 108-109b Carbon tetrachloride C9H6Cl2O3Se·½ H2O C, 33.67/33.56; H, 2.20/1.84; N, 0.00/0.06. 
14 3,5-dimethoxyphenyl 69 117a Toluene C11H12O5Se C, 43.56/43.70; H, 3.96/3.88; N, 0.00/0.00. 
15 3,4,5-trimethoxyphenyl 14 107-110b Ethanol C12H14O6Se C, 43.26/43.32; H, 4.24/3.97; N, 0.00/0.11. 
16 3,4-methylendioxyphenyl 47 106-113b Carbon tetrachloride C10H8O5Se C, 41.83/41.56; H, 2.81/2.67; N, 0.00/0.02. 
17 naphthyl 37 130a Toluene C13H10O3Se C, 53.24/52.99; H, 3.41/3.25; N, 0.00/0.00. 
18 diphenylmethyl 16 127-130b Carbon tetrachloride C16H14O3Se C, 56.90/56.88; H, 4.33/4.11; N, 0.00/0.14. 
19 4-pyridyl 11 119-121b,c Ether / hexane C8H7NO3Se C, 39.36/39.39; H, 2.89/2.78; N, 5.74/5.67. 
20 3-pyridyl 15 147-150b,c Methanol C8H7NO3Se C, 39.36/39.57; H, 2.89/2.76; N,5.74/5.63. 
21 3-(2-chloropyridyl)  157a Toluene C8H6ClNO3Se C, 34.47/34.68; H, 2.15/2.17; N, 5.01/5.26. 
22 3-(2-propylthiopyridyl) 36 109-111b Carbon tetrachloride C11H13NO3SSe C, 41.51/41.28; H, 4.12/3.90; N, 4.40/4.24. 
23 2-thienyl 33 82-84b Carbon tetrachloride C7H6O3SSe C, 33.75/33.45; H, 2.43/2.54; N, 0.00/0.07. 
24 pyrazinyl 10 138-140b Isopropanol C7H6N2O3Se C, 34.30/34.18; H, 2.47/2.49; N, 1.43/1.37. 
25 2-quinolyl 6 131-132b,c Toluene C12H9NO3Se C, 49.00/49.33; H, 3.08/3.13; N, 4.76/4.75. 
26 3-quinolyl 9 187-189b,c Chloroform C12H9NO3Se C, 49.00/48.95; H, 3.08/3.23; N, 4.76/4.66. 
a Determined by differential scanning calorimetry; b Determined by thermomicroscopy; c Fusion with degradation.
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Table 2. Cytotoxic activities of compounds 1–26 against the PC-3 cell line. 
 
Compound R 
PC-3 cell line 
IC50 (μM) 
1 phenyl 6.8 
2 4-cyanophenyl 10.0 
3 4-(trifluoromethyl)phenyl NEa 
4 4-chlorophenyl NE 
5 4-methylphenyl NE 
6 4-tert-butylphenyl NE 
7 4-methoxyphenyl NE 
8 2-chlorophenyl NE 
9 2-bromophenyl NE 
10 2-iodophenyl NE 
11 benzyl 2.9 
12 2-phenylethyl NE 
13 3,5-dichlorophenyl NE 
14 3,5-dimethoxyphenyl 4.0 
15 3,4,5-trimethoxyphenyl NE 
16 3,4-methylenedioxyphenyl NE 
17 naphthyl NE 
18 diphenylmethyl NE 
19 4-pyridyl NE 
20 3-pyridyl NE 
21 3-(2-chloropyridyl) 10.0 
22 3-(2-propylthiopyridyl) NE 
23 2-thienyl NE 
24 pyrazinyl NE 
25 2-quinolyl NE 
26 3-quinolyl NE 
MSAb  8.38 [33] 
Etoposide  13.6 ± 2.2 [34] 
a NE = no effect is observed; b methylseleninic acid. 
Molecular modelling 
From the molecular modelling point of view, three approaches were applied in an effort to gain an 
insight into the structural requirements for activity in these compounds (Figure 2). 
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Figure 2. Overview of structural variations carried out for the studied derivatives: (a) aryl 
or heteroaryl monocyclic derivatives, (b) aryl or heteroaryl bicyclic derivatives. 
(a) 
 
(b) 
 
 
Firstly, it was planned to obtain some descriptive parameter at a molecular level, such as the log of 
the partition coefficient expressed as ALogP and the molecular volume, particularly the volume of the 
aromatic moiety, that would allow discrimination between active and inactive compounds. 
A second approach was carried out. This was based on the pharmacophoric hypothesis that an 
active compound can be characterised by a set of chemical functions with a certain spatial arrangement 
and molecular shape that could be related to the observed biological activity but would not be 
associated with the inactive compounds. Thus, the presence of certain chemical functions is not only 
necessary, but these functions must be exposed in a manner that can be recognised by the associated 
binding site — a property that requires specific conformational behaviour [35]. In agreement with this 
approach, a compound can be considered as a collection of multiple instances, one for each 
conformation. An active compound contains at least one active instance, while an inactive compound 
does not contain any active instance. On the assumption that all of the active compounds bind to the 
same site, we would expect their binding conformations to have similar shapes. For this second 
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approach it is necessary to carry out a study of the conformational behaviour of the compounds and 
subsequently select and analyse the supposed bioactive conformations of the compounds. 
The third approach considered here concerned the structural characteristics of designed molecules, 
especially the presence of the selenium atom, the proposed structural variations related to the length of 
the chain, which acts like a bridge between the keto group and the aromatic or heteroaromatic moiety, 
and the electronic characteristics of the groups located in these rings. These structural variations led us 
to carry out a study from the mechano-quantic point of view in order to obtain data on parameters such 
as the value of the partial charge on the selenium, the energy and distribution of the HOMO and 
LUMO orbitals as well as the electronic density (ED) and molecular electrostatic potential (MEP) 
distribution. The aim was to try to relate these values with the biological activity of our derivatives.  
The calculations were performed on a Dell Precision 380 workstation, provided with the software 
package Discovery Studio v1.7 [36], and on a SGI Virtu VS100 workstation, provided with 
MOPAC2009 [37] and Mercury [38] software packages.  
Once the models for the compounds had been constructed, the initial geometries were fully 
minimized to an energy gradient below 10–3 kcal mol–1Å–1. The minimum energy conformers were 
superimposed, with the ring moiety taken as adjusting atoms. The effectiveness of the superimposed 
models was evaluated in terms of the Root Mean Square (RMS) values obtained. The energy 
differences between the different conformations analysed for each trajectory were in the range  
2–5 kcal.  
Analysis of the resulting data (Tables 3 and 4) enabled the following general observations to be 
made in an attempt to correlate the data with the cytotoxic activity levels found for the compounds on 
the PC-3 cell line. 
1. The permissible maximum volume for the aromatic fragment is approximately 111–112 Å3. 
Thus, the bicyclic compounds (naphthyl, diphenylmethyl and quinolyl derivatives) and the monocyclic 
derivatives with voluminous substituents are inactive. 
2. In relation to the conformational behaviour, it can be observed that, in general, in the 
conformational trajectory of active compounds the number of extended conformations is greater than 
that in the inactive ones, with a better general superposition of the conformations, and the total volume 
of the conformational trajectory is also greater (rms data not shown for the sake of brevity). An 
example is shown in Figure 3. 
3. With respect to the ALogP98 values determined on the preliminary geometries obtained after the 
first minimization (Table 3), although a direct correlation could not be established, the resulting data 
did shed some light on the biological data, since the active products have a value between 1.518 
(compound 21, IC50 = 10.0 μM) and 1.829 (compound 11, the most active compound, IC50 = 2.9 μM). 
As expected, some structural modifications give rise to a marked reduction in the AlogP values, as is 
the case for compounds 19 and 20, derived from pyridine, with a value of 0.644, or for compound 24, 
derived from pyrazine, with a negative value for this parameter. On the other hand, it can be seen that 
the compounds with an AlogP greater than 1.90 are inactive in this assay. 
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Table 3. Molecular descriptors obtained for the analyzed compounds (aryl or heteroaryl monocyclic derivatives) a. 
 
 
 
 
 
 
 
Ref. X Y Z n R2 R3 R4 R5 R6 AlogP Volb D)c IC50(M)e
1 C C C 0 H H H H H 1.795 68.58 3.465 6.8 
2 C C C 0 H H CN H H 1.673 82.16 2.865 10.0 
3 C C C 0 H H CF3 H H 2.737 92.64 1.137 NE 
4 C C C 0 H H Cl H H 2.459 83.19 2.628 NE 
5 C C C 0 H H CH3 H H 2.281 82.76 4.430 NE 
6 C C C 0 H H C(CH3)3 H H 3.195 125.55 4.584 NE 
7 C C C 0 H H OCH3 H H 1.778 89.51 5.337 NE 
8 C C C 0 Cl H H H H 2.459 82.97 2.874 NE 
9 C C C 0 Br H H H H 2.543 91.02 4.032 NE 
10 C C C 0 I H H H H 2.373 100.49 3.259 NE 
11 C C C 1 H H H H H 1.829 82.73 3.418 2.9 
X
Y
R2
R3
R4
R5
R6
z
n
 
O
Se
O
OH
a b
c
d
e
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Table 3. Cont. 
Ref. X Y Z n R2 R3 R4 R5 R6 AlogP Volb D)c IC50(M)d
12 C C C 2 H H H H H 2.286 93.29 4.243 NE 
13 C C C 0 H Cl H Cl H 3.123 98.15 2.441 NE 
14 C C C 0 H OCH3 H OCH3 H 1.762 111.05 4.591 4.0 
15 C C C 0 H OCH3 OCH3 OCH3 H 1.745 131.49 5.090 NE 
16 C C C 0 H -O-CH2-O- H H 1.563 88.78 4.352 NE 
19 C C N 0 H H - H H 0.644 64.45 1.081 NE 
20 N C C 0 H H H H H 0.644 64.64 3.543 NE 
21 N C C 0 Cl H H H H 1.518 78.98 4.094 10.0 
22 N C C 0 S(CH2)2CH3 H H H H 2.597 126.66 4.964 NE 
23 2-thienyl 1.520 64.02 3.315 NE 
24 N N C 0 H H H H - -0.078 60.35 3.096 NE 
MSA - - - - - - - - - - - - 8.38 
Etoposide - - - - - - - - - - - - 13.6 ±2.2 
a General structure for the analysed compounds showing the bonds (a–e) selected for the conformational analysis. b Volume (average 
value obtained from the lowest energy conformations) of the cyclic fragment in Å 3. c Dipolar moment (in Debyes) calculated for the 
representative low-energy. d Cytotoxic activity in PC-3 cell line, NE= no effect. 
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Table 4. Molecular descriptors obtained for the analyzed compounds (aryl or heteroaryl 
bicyclic derivatives) a. 
 
 
 
 
 
Ref. R AlogP Volb D)c IC50(M)d 
17 naphthyl 2.703 106.65 3.759 NE 
18 diphenylmethyl 3.324 144.34 3.632 NE 
25 2-quinolyl 2.409 102.41 4.451 NE 
26 3-quinolyl 1.981 102.22 2.685 NE 
MSA - - - - 8.38 
Etoposide - - - - 13.6 ±2.2 
a General structure for the analysed compounds showing the bonds (a–d) selected for the 
conformational analysis. b Volume (average value obtained from the lowest energy conformations) 
of the cyclic fragment in Å 3. c Dipolar moment (in Debyes) calculated for the representative low-
energy conformation. d Cytotoxic activity in PC-3 cell line, NE= no effect. 
Figure 3. Conformational models for some representative compounds: (a) active 
compounds, left 11; right 1; (b) inactive compounds: left 12; right 6. Carbon in green; 
hydrogen in grey; oxygen in red; selenium in violet. 
  
(a) 
 
(b) 
R
O
Se
O
OH
a
b
c
d
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4. With respect to the length of the bridging chain between the aromatic moiety and the keto group, 
the introduction of a methylene fragment significantly improves the activity (IC50 = 6.8 μM for 
compound 1 and IC50 = 2.9 μM for compound 11; Table 3 and Figure 4c). However, the introduction 
of a second methylene leads to the disappearance of the activity. This change could be related to the 
conformational behaviour. For example, in compound 12 the preferred conformations are the folded 
ones (see Figure 4c). 
Figure 4. Influence of the alkyl chain and ring on the HOMO 0 (a), LUMO 0 (b) 
distribution, valuated as descriptive parameters, showed on a low-energy representative 
conformation (c). Carbon in cyan; hydrogen in white; oxygen in red; selenium in violet; 
sulphur in yellow. 
(a) (b) (c) 
 
1 
 
 
11 
  
 
12 
  
 
23 
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5. As regards the dipolar moment, a correlation could not be established and great variability was 
observed for this parameter, even within the conformational trajectory of each individual compound. 
6. With respect to the descriptor parameters obtained by quantum chemistry semi-empirical 
calculations, the structural variations that lead to a negative value for the partial charge on the 
selenium lead to the loss of activity. Concerning the distribution of the frontier molecular orbitals (see 
4a, 4b, 5a and 5b), it was also found that in the most active compounds the HOMO orbital is 
preferentially located on the selenium, with a significant contribution from carbons of the aromatic 
nucleus. In general it can be observed that the presence of substituents in the 4-position brings about 
the displacement of the HOMO towards the ring, with the contribution of selenium decreasing along 
with the activity. As an example, the distribution of this orbital for compounds 1 (IC50 = 6.8 μM, 
Figure 4a) and 2 (IC50 = 10.0 μM, Figure 5a) can be compared with that of compound 7, which 
contains a methoxy group and is inactive. Nevertheless a correlation with the data of energy for orbital 
HOMO and LUMO, nor with the gap (LUMO-HOMO energy) cannot be established (Tables 5 and 6). 
Figure 5. Influence of the substituents placed in 4-position on the HOMO 0 (a), LUMO 0 
(b) distribution, valuated as descriptive parameters, showed on a low-energy representative 
conformation (c). Carbon in cyan; hydrogen in white; oxygen in red; selenium in violet; 
nitrogen in blue; chlorine in green. 
(a) (b) (c) 
 
2 
 
4 
 
 
 
7 
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Table 5. Mechano-quantic descriptive parameters (semiempirical: PM6) obtained for the analyzed compounds (aryl or heteroaryl monocyclic 
derivatives). 
 
 
 
 
Ref. X Y Z n R2 R3 R4 R5 R6 pKab 
Bond order HOMOc LUMOd EL-M Q_See 
IC50 
a b c (M)f 
1 C C C 0 H H H H H 2,119 1,8315 0,9068 0,9618 -9,210 -1,552 7,658 0.0577 6.8 
2 C C C 0 H H CN H H 2,057 1,8478 0,9050 0,9608 -9,422 -2,022 7,400 0.0778 10.0 
3 C C C 0 H H CF3 H H 2,148 1,8492 0,9048 0,9608 -9,399 -1,894 7,505 -0.0303 NE 
4 C C C 0 H H Cl H H 2,188 1,7914 0,9659 0,9624 -9,382 -1,666 7,716 -0.0394 NE 
5 C C C 0 H H CH3 H H 2,184 1,8230 0,9037 0,9613 -9,002 -1,487 7,515 0.0491 NE 
6 C C C 0 H H C(CH3)3 H H 2,182 1,8256 0,9027 0,9611 -9,108 -1,403 7,705 0.0485 NE 
7 C C C 0 H H OCH3 H H 2,196 1,8159 0,8940 0,9592 -9,039 -1,208 7,831 0.0433 NE 
8 C C C 0 Cl H H H H 2,360 1,8508 0,9320 0,9673 -9,258 -1,384 7,874 0.0292 NE 
9 C C C 0 Br H H H H 2,346 1,8611 0,9172 0,9524 -9,295 -1,244 8,051 0.0134 NE 
10 C C C 0 I H H H H 2,388 1,8721 0,9069 0,9626 -8,864 -1,582 7,282 -0.0182 NE 
11 C C C 1 H H H H H 2,370 1,8419 0,9742 0,9841 -9,439 -0,936 8,503 0.0681 2.9 
12 C C C 2 H H H H H 2,378 1,8360 0,9799 0,9622 -9,485 -1,138 8,347 0.0580 NE 
13 C C C 0 H Cl H Cl H 1,858 1,8482 0,9123 0,9626 -9,410 -1,961 7,449 -0.0331 NE 
14 C C C 0 H OCH3 H OCH3 H 2,791 1,9205 0,9126 0,9673 -9,275 -1,063 8,212 0.0693 4.0 
15 C C C 0 H OCH3 OCH3 OCH3 H 2,431 1,8021 0,9528 0,9633 -8,770 -1,329 7,441 0.0652 NE 
16 C C C 0 H -OCH2O- H H 2,083 1,8413 0,9068 0,9620 -9,223 -1,630 7,593 0.0720 NE 
19 C C N 0 H H - H H 1,985 1,7891 0,9918 0,9766 -9,546 -1,717 7,829 0.0825 NE 
20 N C C 0 H H H H H 2,230 1,7775 0,9840 0,9767 -9,483 -1,663 7,820 0.0712 NE 
21 N C C 0 Cl H H H H 2,145 1,8279 0,9540 0,9686 -9,368 -1,712 7,656 0.0129 10.0 
22 N C C 0 S(CH2)2CH3 H H H H 2,486 1,8722 0,8969 0,9628 -8,871 -1,585 7,286 -0.0093 NE 
23     2-thienyl     2,181 1,7872 0,9417 0,9598 -9,204 -1,696 7,508 -0.0438 NE 
24 N N C 0 H H H H - 1,813 1,7829 1,0108 0,9746 -9,406 -2,030 7,376 0.1126 NE 
X
Y
R2
R3
R4
R5
R6
z
n
 
O
Se
O
OH
a
b c
Molecules 2009, 14  
  
3327
Table 6. Mechano-quantic descriptive parameters (semiempirical: PM6) obtained for the 
analyzed compounds (aryl or heteroaryl bicyclic derivatives) a. 
 
 
 
 
Ref. R pKab 
Bond order 
HOMOc LUMOd 
EL-
M
 Q_Se
e IC50 
a b c (M)f 
17 Naphtyl 2,655 1,8432 0,8921 0,9578 -9,076 -1,647 7,429 0.0644 NE 
18 Diphenylmethyl 2,592 1,8829 0,9492 0,9689 -9,456 -1,110 8,346 0.0598 NE 
25 2-quinolyl 2,306 1,7884 1,0012 0,9606 -9,214 -1,918 7,296 0.0918 NE 
26 3-quinolyl 2,375 1,8453 0,8972 0,9589 -9,222 -1,881 7,341 0.0619 NE 
Notes for Tables 5-6: a General structure for the analyzed compounds showing the bonds (a-b) 
selected for the bond order determination. b pKa value calculated for the low-energy representative 
conformation c HOMO 0 orbital energy, in eV, calculated for the low-energy representative 
conformation d LUMO 0 orbital energy, in eV, calculated for the low-energy representative 
conformation e Charge on Selenium atom, value obtained for the low-energy representative 
conformation. fCytotoxic activity in PC-3 cell line, NE= no effect. 
 
7. With respect to the bond order (Tables 5 and 6) a correlation with the activity cannot be 
established, which contradicts our starting hypothesis related to the stability of the C-Se bond.  
8. In relation to the acidic character evaluated by the pKa values (Tables 5 and 6), the values of pKa 
for the most active compounds oscillate between 2.05 and 2.80, although the proposed structural 
modifications apparently do not affect in a significant manner this parameter. 
In the present state of our research on these selenium derivatives, we do not try to propose a 
pharmacophore applying only a conformacional analysis. We have carried out a conformacional 
analysis in order to obtain data about the conformacional behavior of these molecules, with a high 
degree of conformational freedom, and to sample what are the preferred conformations, between that 
we hoped to find the bioactive one. 
Cytotoxic activity in CCRF-CEM, HTB-54, HT-29, MCF-7 and 184B5 
In order to investigate the effect of the active compounds in more detail, we examined the activity 
on proliferation in other cancer cell lines. The most active compounds in PC-3 were tested, along with 
the reference compound doxorubicin, for cytotoxic and antiproliferative activities. Tests were carried 
out in the Department of Health Science, Public University of Navarra against a panel of four human 
tumour cell lines: lung (HTB-54), colon (HT-29), leukaemia (CCRF-CEM) and breast adenocarcinoma 
(MCF-7). Cytotoxicity assays were performed based on the reactivity of MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide], as described by NCI [39]. The results are expressed as GI50 
values, i.e., the concentration that reduces by 50% the growth of treated cells with respect to untreated 
controls, TGI, the dose that completely inhibits cell growth, and LD50, the concentration that kills 50% 
of the cells. The cytotoxic effect of each substance was tested at five different doses between 0.01 and 
R
O
Se
O
OHa
b c
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100 μM, or at lower levels when the GI50 was less than 10 nM. Mean GI50, TGI, and LD50 values are 
summarized in Table 7. Doxorubicin was used as a control. As guidance with regard to selectivity, all 
of the compounds were further examined for toxicity in a mammary gland cell culture derived from 
non-malignant cells (184B5). Drug concentrations ranged from 0.01 to 100 μM. 
Table 7. Cytotoxic activities (average GI50a, TGIb and LD50c values) for compounds 
against tumour cell lines. 
Comp. 
C.Pa (μM) Cell lines 
 CCRF-CEM HTB-54 HT-29 MCF-7 184B5 
1 bGI50 >100 0.58 7.39 0.09 1.97 
 
cTGI >100 42.47 55.98 3.69 22.50 
dLD50 >100 >100 >100 58.01 76.73 
2 GI50 >100 1.90 8.95 2.64 2.29 
 
TGI >100 9.91 51.95 6.54 20.14 
LD50 >100 >100 >100 23.12 78.91 
11 GI50 >100 11.14 16.19 0.006 1.05 
 
TGI >100 >100 72.19 4.18 9.64 
LD50 >100 >100 >100 53.49 72.34 
14 GI50 >100 16.82 5.99 1.57 0.0009 
 
TGI >100 >100 47.42 6.19 8.21 
LD50 >100 >100 >100 52.65 62.55 
21 GI50 >100 11.79 7.53 0.003 0.05 
 
TGI >100 >100 60.94 8.27 1.89 
LD50 >100 >100 >100 89.21 7.20 
Doxorub. GI50 0.033 <0.01 nde 0.88 nd 
 
TGI 0.071 1.25 nd >100 nd 
LD50 0.29 3.45 nd >100 nd 
a Cytotoxic parameters ; b Dose that inhibits 50% of cell growth; c Dose that completely 
inhibits cell growth; d Dose that kills 50% of cells; e n.d.: not determined. 
 
The data show that the compounds under investigation influenced tumour cell growth differently 
depending on the cell line. The human breast adenocarcinoma cell line (MCF-7) was most sensitive to 
the antiproliferative effects of the investigated compounds. In particular, 1 (GI50 = 0.09 μM), 11  
(GI50 = 0.006 μM), 14 (GI50 = 1.57 μM ) and 21 (GI50 = 0.003 μM) were strongly antiproliferative. 
Compounds 1, 11 and 21 were 10, 147 and 293 times more active, respectively, than standard 
doxorubicin (GI50 = 0.88 μM). Besides, if we compare the TGI values for these compounds  
(TGI = 3.69, 4.18, 6.19 and 8.27 μM, respectively), all of them are lower than that of doxorubicin. In 
addition, 11 and 21 exhibited a better antitumoral profile than paclitaxel (GI50 = 0.010 ± 0.04 and TGI 
= 20 ± 1.9 μM) and vinorelbine (GI50 = 5 ± 1.3 and TGI = 100 ± 10.2 μM), both drugs that are widely 
used in clinic. The least sensitive cell line was CCRF-CEM leukemia with cytotoxic parameters  
>100 μM for all the compounds. HT-29 and HTB-54 showed moderate levels of susceptibility to the 
compounds with the exceptions of 1 (GI50 = 7.39 and 0.58 μM) and 2 (GI50 = 8.95 and 1.90 μM).  
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As an example, curves with the original data from which the GI50, TGI and LD50 values for 
compounds 1 and 2 were calculated are shown in Figure 6. Fortunately, the LD50 in 184B5 is higher 
than in MCF-7 and the selectivity indexes are 1.3 and 3.4, respectively (184B5/MCF-7 LD50 ratio). 
Figure 6. Cytotoxic effects of 1 and 2 on CCRF-CEM, HTB-54, HT-29, MCF-7 and 
184B5 cells. Cells were incubated in the presence of each compound at the indicated 
concentration for 72 hours. Cytotoxicity was then determined by a colorimetric microassay 
based on the use of MTT. Data are expressed as percentage growth ± SEM from at least 3 
independent experiments performed in quadruplicate. 
 
 
It is evident that compound 1 displayed the most prominent antiproliferative activity against all 
treated cell lines compared to the untreated control. This compound is therefore a representative 
candidate for these compounds for preliminary studies in order to explore a possible mechanism of 
action. 
Apoptosis 
Mounting evidence indicates that apoptosis is a critical mechanism for cancer prevention by Se 
compounds [40,41]. For this reason, we investigated whether apoptosis was involved in cell growth 
inhibition in the MCF-7 cells by 1. 
The apoptotic status of the cells after 48 hours of treatment with 25 μM of the corresponding 
compound was determined using the Apo-Direct kit (BD Pharmingen) [42] based on the TUNEL 
technique. Camptothecin was used as a positive control. The results obtained are shown in Figure 7. 
As can be seen, for compound 1 the induction of cell death was independent of the apoptotic process. 
Effects on cell cycle progression 
Cell cycle arrest is one of the targets of many anticancer drugs, including doxorubicin and 
camptothecin. In an effort to ascertain whether compound 1 could affect cell cycle progression in 
MCF-7 cells, these cells were treated with 25 M of the corresponding compound for 48 hours and 
cell cycle progression was determined by flow cytometry analysis [42]. As shown in Figure 8, DNA 
flow cytometric analysis indicated that treatment of the cells with compound 1 did not induce any 
specific phase arrest of the cell cycle. 
Molecules 2009, 14                            
 
 
3330
Figure 7. MCF-7 cells were incubated either with 25 µM of the indicated compound or 
vehicle (control cells) for 48 hours. The results are presented as the mean ± SEM of three 
independent experiments (duplicate wells). * p < 0.01 with respect to the control. 
 
 
Figure 8. Cell cycle phase distribution of MCF-7 cells after 48 hours of treatment with 25 
M of the indicated compound or vehicle (control). Results are expressed as percentages 
of total cell counts. Each bar represents mean ± SEM of three independent experiments 
(duplicate wells). 
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Conclusions 
In summary, we have synthesized a series of 26 aroyl and heteroaroyl selenylacetic acids and 
evaluated the cytotoxicity against a prostate cancer cell line (PC-3). Five compounds (1, 2, 11, 14 and 
21) showed interesting activity and three of them (1, 11 and 14) were more powerful than etoposide 
and methylseleninic acid. Exploration of the SAR study suggested that the permissible maximum 
volume for the aromatic fragment is approximately 111–112 Å. A study of the ALogP data indicated 
that the compounds with values much greater than 1.90 were inactive. In terms of the length of the 
bridging chain between the aromatic moiety and the keto group, the presence of a methylene fragment 
improves the activity. We also tested some selected compounds against a panel of four human tumoral 
cell lines (CCRF-CEM, HTB-54, HT-29, MCF-7) and one mammary gland-derived non-malignant cell 
line (184B5). Compounds 1, 11 and 21 exhibited excellent growth inhibition activity against MCF-7, 
with values in the nanomolar range, and moderate values in HTB-54 and HT-29. However, these 
compounds did not show inhibitory potency against CCRF-CEM. Comparable activity was observed 
on two of the cell lines studied, one a hormone-independent prostate (PC-3) and the other a hormone-
dependent MCF-7 breast cancer cell line. This could suggest that the mode of action is to a large extent 
unrelated to the expression of the androgen receptor (PC-3 negative) and oestrogen receptor (MCF-7 
positive). Compound 1, which exhibited the best profile, was examined as an apoptotic agent and cell 
cycle modulator in MCF-7. The preliminary results revealed that the mechanism of action is 
independent of apoptosis and additional studies are required to determine the mechanism by which this 
compound exerts its activity. This work is currently in progress in our laboratory. The results reported 
here open up new perspectives for future investigations into the synthesis of new compounds of this 
family and these are potentially useful for the modulation of pharmacological potential with enhanced 
and selective anticancer activity.  
Experimental 
General 
Melting points were determined by differential scanning calorimetry with a Perkin-Elmer DSC 
Diamond and by thermomicroscopy with a Mettler FP82+FP80 apparatus (Greifense, Switzerland) and 
have not been corrected. The 1H NMR spectra (Table 8) were recorded on a Bruker 400 UltrashieldTM 
(Rheinstetten, Germany), using TMS as the internal standard (Table 8). The IR spectra (Table 8) were 
performed on a Thermo Nicolet FT-IR Nexus in KBr pellets (Table 8). Elemental microanalyses were 
carried out on vacuum-dried samples (Table 1) using an Elemental Analyser (LECO, CHN-900 
Elemental Analyser). Silica gel 60 (0.040–0.063 mm) 1.09385.2500 (Merck KGaA, 64271 Darmstadt, 
Germany) was used for Column Chromatography and Alugram SIL G/UV254 (Layer: 0.2 mm) 
(Macherey-Nagel GmbH & Co. KG. Postfach 101352. D-52313 Düren, Germany) was used for Thin 
Layer Chromatography. Chemicals were purchased from E. Merck (Darmstadt, Germany), Scharlau 
(F.E.R.O.S.A., Barcelona, Spain), Panreac Química S.A. (Montcada i Reixac, Barcelona, Spain), 
Sigma-Aldrich Química, S.A. (Alcobendas, Madrid, Spain), Acros Organics (Janssen 
Pharmaceuticalaan 3a, 2440 Geel, België), Maybridge (Cambridge, CB5 8BZ, UK) and Lancaster 
(Bischheim-Strasbourg, France). 
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Table 8. Spectroscopic data for compounds 1–26. 
Ref. IR (KBr, υ in cm-1) 1H NMR (400 MHz, δ/ppm, J in Hz) 
1 1702, 1678 DMSO-d6, 3.81 (s, 2H, Se-CH2-COOH), 7.59 (m, 2H, H3 + H5), 7.75 (tt, 1H, H4, J4-
5=J4-3=7.9, J4-6=J4-2=1.2), 7.90 (dd, 2H, H2 + H6, J6-5=J2-3=8.4), 12.80 (br s, 1H, 
COOH). 
2 2232, 1681 CDCl3, 3.91 (s, 2H, Se-CH2-COOH), 7.81 (d, 2H, H3 + H5, J3-2=J5-6=8.7), 8.00 (d, 2H, 
H2 + H6). 
3 1694, 1712 CDCl3 3.91 (s, 2H, Se-CH2-COOH), 7.78 (dd, 2H, H3+ H5, J3-2=J5-6=8.1, J3-CF3=J5-
CF3=0.5), 8.02 (dd, 2H, H2 + H6, J2-CF3=J6-CF3=0.6). 
4 1697, 1686 DMSO-d6, 3.81 (s, 2H, Se-CH2-COOH), 7.66 (d, 2H, H3+H5; J3-2= J5-6=8.5), 7.91 (d, 
2H, H2+H6), 12.89 (br s, 1H, COOH). 
5 1691 CDCl3, 2.43 (s, 3H, CH3), 3.85 (s, 2H, Se-CH2-COOH), 7.29 (d, 2H, H3+ H5, J3-2=J5-6= 
8.1), 7.81 (d, 2H, H2 + H6). 
6 1715, 1666 CDCl3, 1.36 (s, 9H, C-(CH3)3), 3.85 (s, 2H, Se-CH2-COOH), 7.51 (d, 2H, H3+H5, J3-2= 
J5-6=8.7), 7.86 (d, 2H, H2+H6).  
7 1707, 1692 CDCl3, 3.83 (s, 2H, Se-CH2-COOH), 3.91 (s, 3H, CH3O), 6.97 (d, 2H, H3+H5, J3-2= 
9.0), 7.90 (d, 2H, H2+H6).  
8 1707, 1688 CDCl3, 3.89 (s, 2H, Se-CH2-COOH), 7.37-7.43 (m, 1H, H5), 7.49-7.50 (m, 2H, 
H4+H3), 7.76-7.79 (m, 1H, H6). 
9 1703, 1684 CDCl3, 3.89 (s, 2H, Se-CH2-COOH), 7.40 (tt, 1H, H5, J5-6=1.8, J5-4=7.5 J5-3=8.9), 7.44 
(tt, 1H, H4, J4-3=1.4 Hz, J4-6=7.6), 7.70 (dd, 1H, H3), 7.72 (dd, 1H, H6). 
10 1701, 1677 CDCl3, 3.90 (s, 2H, Se-CH2-COOH), 7.23 (dt, 1H, H5, J5-3=1.5, J5-6=7.9, J5-4=7.7), 7.48 
(dt, 1H, H4, J4-6=0.4, J4-3=7.7), 7.69 (dd, 1H, H3); 8.00 (dd, 1H, H6). 
11 1694, 1685 CDCl3, 3.62 (s, 2H, Se-CH2-COOH), 3.90 (s, 2H, Ar-CH2-COSe), 7.32 (m, 2H, H3 + 
H5), 7.38 (m, 3H, H2 + H4 + H6). 
12 1708, 1686 CDCl3, 3.03 (s, 4H, Ar-CH2-CH2-COSe + Ar-CH2-CH2-COSe), 3.69 (s, 2H, Se-CH2-
COOH), 7.20-7.26 (m, 3H, H3+H4+H5), 7.30-7.34 (m, 2H, H2+H6). 
13 1699, 1667 CDCl3, 3.84 (s, 2H, Se-CH2-COOH), 7.57 (s, 1H, H4), 7.70 (s, 2H, H2+H6), 8.44 (br s, 
1H, COOH). 
14 1714, 1696 CDCl3, 3.85 - 3.86 (s + s, 8H, 2 OCH3 + Se-CH2-COOH, JCH2-Se=72.2), 6.72 (dt, 1H, 
H4, J4-2=J4-6=0.8 Hz, J4-OCH3=2.3), 7.04 (dd, 2H, H2 + H6, J2-OCH3=J6-OCH3=2.2). 
15 1703, 1671 CDCl3, 3.86 (s, 2H, Se-CH2-COOH), 3.94 (s, 6H, 3,5-diCH3O), 3.95 (s, 3H, 4-CH3O), 
7.16 (s, 2H, H2). 
16 1701, 1675 DMSO-d6, 3.76 (s, 2H, Se-CH2-COOH), 6.18 (s, 2H, O-CH2-O), 7.09 (dd, 1H, H5, J5-
2= 0.9 Hz, J5-6=7.8), 7.34 (dd, 1H, H2, J2-6=2.9), 7.55 (dd, 1H, H6), 12.79 (br s, 1H, 
COOH). 
17 1719, 1671 CDCl3, 3.92 (s, 2H, Se-CH2-COOH), 4.40 (br s, 1H, COOH), 7.63 (m, 2H, H4+ H5), 
7.91 (m, 3H, H3 + H6 + H7), 8.00 (d, 1H, H8, J8-7=8.1), 8.48 (s, 1H, H2). 
18 1720, 1693 CDCl3, 3.68 (s, 2H, Se-CH2-COOH), 5.23 (s, 1H, (Ph)2-CH-COSe), 7.31-7.40 (m, 10 
H, 2H2, 2H6, 2H3, 2H5, 2 H4). 
19 1717, 1659  DMSO–d6, 3,87 (s, 2H, Se-CH2-COOH), 7,78 (td, 2H, H3+H5), 8,85 (td, 2H, 
H2+H6). 
20 1713, 1673 DMSO-d6, 3.87 (s, 2H, Se-CH2-COOH), 7.61-7.65 (m, 1H, H5), 8.26-8.30 (m, 1H, H4), 
8.87-8.90 (m, 1H, H6), 9.02-9.03 (m, 1H, H2), 12.84 (br s, 1H, COOH). 
21 1724, 1690 DMSO-d6, 3.87 (s, 2H, Se-CH2-COOH), 7.63 (ddd, 1H, H5, J5-4=7.7, J5-6=4.8, J5-Cl= 
1.1), 8.24 (ddd, 1H, H4, J4-Cl=1.1), 8.63 (ddd, 1H, H6, J6-Cl=1.1), 12.90 (br s, 1H, 
COOH). 
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Table 18. Cont. 
22 1700, 1668 DMSO-d6, 0.97 (t, 3H, CH3), 1.58-1.70 (m, 2H, S-CH2-CH2-CH3), 3.11 (dt, 2H, S-
CH2-CH2-CH3), 3.81 (s, 2H, Se-CH2-COOH), 7.32 (dd, 1H, H4, J4-5=4.8, J4-6=7.8), 
7.97 (dt, 1H, H5, J5-6=1.7), 8.29 (dd, 1H, H6), 12.89 (br s, 1H, COOH). 
23 1712, 1643 DMSO-d6, 3.80 (s, 2H, Se-CH2-COOH), 7.30 (dd, 1H, H4, J4-5=3.9 Hz, J4-3=4.9 Hz), 
8.02 (dd, 1H, H5, J5-3=1.1 Hz), 8.16 (dd, 1H, H3), 12.82 (bs, 1H, COOH). 
24 1703, 1674 DMSO-d6, 3.74 (s, 2H, Se-CH2-COOH), 8.87 (dd, 1H, H6, J6-3=1.2 Hz, J6-5=2.4 Hz), 
9.05 (dd, 1H, H5, J5-3=0.2 Hz), 9.06 (dd, 1H, H3), 12.73 (br s, 1H, COOH). 
25 1714, 1690 DMSO-d6, 3.73 (s, 2H, Se-CH2-COOH), 7.82 (t, 1H, H7, J7-6=7.5, J7-8=8.0), 7.94 (t, 
1H, H6, J6-5=8.3), 7.97 (d, 1H, H5), 8.15 (d, 1H, H8), 8.19 (d, 1H, H3, J3-4=8.4), 8.66 (d, 
1H, H4), 12.68 (br s, 1H, COOH). 
26 1709, 1675 DMSO-d6, 3,91 (s, 2H, Se-CH2-COOH), 7,77 (t, 1H, H6, J6-7=7,6 ), 7,98 (t, 1H, H7), 
8,13 (d, 1H, H5, J5-8=8,3), 8,31 (d, 1H, H8), 9,07 (d, 1H, H4, J4-2=1,8), 9,23 (d, 1H, 
H2),12,75 (bs, 1H, COOH).  
General procedure for the preparation of selenylacetic acids 1–6, 8–26 
A solution of sodium borohydride (1.00 g, 26.3 mmol) in distilled water (12.5 mL) was added to a 
stirred suspension of grey selenium (1.00 g, 12.6 mmol) in distilled water (12.5 mL) at room tempera-
ture. The reaction mixture was stirred until an almost colourless solution of NaHSe was formed. The 
acyl chloride (12.6 mmol) was added in small portions and the reaction mixture was magnetically stirred 
for 1 hour. A yellow solution was formed and the bromoacetic acid (1.75 g, 12.6 mmol) was added. 
Within 30 minutes a solid was formed. The product was filtered off and washed with distilled water  
(3 × 25 mL). The products were recrystallised from an appropriate solvent (Table 1). The following 
compounds were synthesized according to this procedure: (Benzoylselenyl)acetic acid (1). (4-
cyanobenzoylselenyl)acetic acid (2). (4-trifluoromethylbenzoylselenyl)acetic acid (3). (4-
chlorobenzoylselenyl)acetic acid (4). (4-methylbenzoylselenyl)acetic acid (5). (4-tert-butylbenzoyl-
selenyl)acetic acid (6). (2-chlorobenzoylselenyl)acetic acid (8). (2-bromobenzoylselenyl)acetic acid 
(9). (2-iodobenzoylselenyl)acetic acid (10). Phenylacetoylselenylacetic acid (11). (3-phenyl-
propanonylselenyl)acetic acid (12). (3,5-dichlorobenzoylselenyl)acetic acid (13). (3,5-dimethoxy-
benzoylselenyl)acetic acid (14). (3,4,5-trimethoxybenzoylselenyl)acetic acid (15). (3,4-methylenedioxy-
benzoylselenyl) acetic acid (16). (2-naphthoylselenyl)acetic acid (17). (diphenylacetylselenyl)acetic 
acid (18). (4-pyridoylselenyl)acetic acid (19). (3-pyridoylselenyl)acetic acid (20). (3-(2-chloro)-
pyridoylselenyl)acetic acid (21). (3-(2-propylthio)pyridoylselenyl)acetic acid (22). (2-thienoylselenyl)-
acetic acid (23). (pyrazinoylselenyl)acetic acid (24). (2-quinoloylselenyl)acetic acid (25). (3-
quinoloylselenyl)acetic acid (26). 
Procedure for the preparation of (4-methoxyphenylselenyl)acetic acid  (7) 
An equivalent of grey-powder selenium was suspended in tetrahydrofuran (20 mL) and two 
equivalents of lithium aluminium hydride were added slowly. The carbonyl chloride was added to the 
reaction mixture and the mixture was stirred for 1 h. The suspension was filtered and the solid was 
discarded. An equivalent of bromoacetic acid was added to the liquid filtrate. After 20 min the mixture 
was poured onto 500 g of ice. The resulting solid was filtered off, washed and recrystallised (Table 1). 
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Cytotoxic activity in PC-3 
PC-3 cells were seeded in 96-well plates (Millipore, Eschborn, Germany) at a density of 5 × 103 
cells per well. The samples were incubated at 37 ºC under 5% CO2 overnight prior to the addition of 
the compounds. Compounds were diluted in complete medium. After 3 days of incubation, 10 μL MTT 
solution (5 mg/mL in PBS) was added to the cells in each well and these were stored for an additional 
4 h at 37 ºC. The absorbance of formazan at λ = 570 nm was measured on a Polarstar Galaxy plate 
reader (BMG LabTechnologies GmbH, Offenburg, Germany). The percentage of viable cells was 
calculated to obtain IC50-values. 
PC-3 are human tumorigenic and metastatic prostate cancer cells and these were obtained from 
American Type Culture Collection (ATCC, Manassas, VA, USA) (passage 36). The cells were 
cultured under standard conditions (Dulbecco’s RPMI 1640 medium, with GlutamaxTM 1, Invitrogen 
supplemented with 10% fetal bovine serum, Fetalclone III, SH30109.03, HYCLONE and 1% 
Penicillin-Streptomycin, Invitrogen, Carlsbad, CA, USA).  
Molecular modelling 
The initial computational work was performed on a Dell Precision 380 workstation, provided with 
the software package Discovery Studio v1.7. The three-dimensional models of the studied compounds 
were constructed, in the vacuum phase, using atoms and structural fragments from the Viewer module 
(Discovery Studio) and using the Dreiding force field [43]. Once the models were constructed, a 
preliminary conformational analysis was carried out. The applied protocol (Diverse Conformational 
Generation integrated in the Pharmacophore protocol Discovery Studio) can be summed up as follows: 
(a) Initial construction of the model and first minimization by application of the Dreiding minimize 
protocol (Steepest descent algorithm with a convergence criterion of 10–6). The AlogP98 [44,45] 
descriptor (an implementation of the atom-based ALogP method) was calculated for each compound. 
(b) Application of the BEST routine for conformation generation (First: Conjugate-gradient 
minimization in torsion space; second: conjugate-gradient minimization in Cartesian space; third: 
Quasi_Newton minimization in Cartesian space). (c) Elimination of those conformations whose 
relative energy is greater than 10 Kcal/mol at a global minimum. (d) Analysis of conformational 
trajectory and selection of representative lowest energy conformations. Root mean square (rms) 
deviations of the structures were monitored. The energy differences between the different 
conformations analysed for each trajectory were in the range 2–5 Kcal.  
For each of the compounds, ten lowest energy conformations were selected and a new minimization 
cycle was applied. The volumes of the ring moiety and the whole molecule were calculated for each of 
the new representative low-energy conformations selected. 
The mechano-quantic analysis of the conformations obtained in the previous step was carried out 
with the package Mopac2009, PM6 [46] (or PM3 [47] for halogen and/or sulfur-containing 
derivatives) semi-empirical approaches, with the geometry optimized using an eigenvector following 
algorithm. The energy and distribution of the HOMO and LUMO orbitals, the selenium charge, the 
electronic density (ED) and molecular electrostatic potential (MEP) distribution and the Dipolar 
moment were obtained for each of the conformations obtained. The data corresponding to the 
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representative lowest energy conformation for each compound was selected and used in the 
establishment of the preliminary structure-activity relationships. 
Cytotoxic activity in CCRF-CEM, HTB-54, HT-29, MCF-7 and 184B5  
The cytotoxic effects of each substance were tested at five different doses between 0.01 and  
100 μM. Each substance was initially dissolved in DMSO at a concentration of 0.1 M, and serial 
dilutions were prepared using culture medium. The plates with cells from the different lines, to which 
medium containing the substance under test were added, were incubated for 72 h at 37 °C in a 
humidified atmosphere containing 5% CO2. European Collection of Cell Cultures (ECACC) or 
American Type Culture Collection (ATCC) provided human tumour cell lines. Four cell lines were 
used: one human lymphocytic leukemia (CCRF-CEM) and three human solid tumours, one colon 
carcinoma (HT-29), one lung carcinoma (HTB-54) and one breast adenocarcinoma (MCF-7). CCRF-
CEM, HT-29 and HTB-54 cells were grown in RPMI 1640 medium (Life Technologies, Carlsbad, CA, 
USA) supplemented with 10% foetal calf serum, 2 mM L-glutamine, 100 units/mL penicillin, 100 
μg/mL streptomycin and 10 mM HEPES buffer (pH = 7.4). MCF-7 cells were grown in EMEM 
medium (Clonetics) supplemented with 10% foetal calf serum, 2 mM L-glutamine, 100 units/mL 
penicillin and 100 μg/mL streptomycin. 184B5 cells were grown Hams F-12/DMEM (50:50) 
supplemented as described by Li et al. [48]. Cytotoxicity was then determined by the MTT method. 
Results are expressed as GI50 values, the concentration that reduces by 50% the growth of treated cells 
with respect to untreated controls, TGI, the dose that completely inhibits cell growth, and LD50, the 
concentration that kills 50% of the cells. Data were obtained from at least three independent 
experiments performed in quadruplicate. 
Apoptosis and cell cycle 
For breast adenocarcinoma MCF-7 cells, the apoptotic status and cell cycle analysis of the cells 
were determined using the Apo-Direct kit (BD Pharmingen), based on the TUNEL technique, under 
the conditions described by the manufacturer.  
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